Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Palvella Therapeutics outlines robust 2026 roadmap for QTORIN platform

Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.

Leia mais: Palvella Therapeutics outlines robust 2026 roadmap for QTORIN platform
Grafa

Kroger unloads Vitacost to iHerb in push to streamline retail portfolio

The Kroger Company (NYSE:KR) completed the sale of its online health-and-wellness subsidiary, Vitacost.com, to iHerb on Friday, a move aimed at excising non-core digital assets as the grocery giant narrows its focus on its primary retail operations and high-return business lines.

Leia mais: Kroger unloads Vitacost to iHerb in push to streamline retail portfolio
Grafa
Health

Aquestive Therapeutics faces FDA-identified deficiencies in Anaphylm NDA

Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.

Leia mais: Aquestive Therapeutics faces FDA-identified deficiencies in Anaphylm NDA
Grafa
Health

Perspective Therapeutics reports 39% response rate in breakthrough alpha-radiopharmaceutical trial

Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.

Leia mais: Perspective Therapeutics reports 39% response rate in breakthrough alpha-radiopharmaceutical trial
Grafa
Health

Amarin ighhlights VASCEPA/VAZKEPA positioning amid advances in triglyceride management

Amarin Corporation (NASDAQ:AMRN) commented on recent therapeutic advances for patients with elevated triglycerides, asserting that its flagship VASCEPA/VAZKEPA (icosapent ethyl) franchise remains strongly positioned to benefit from broader category commercialization efforts.

Leia mais: Amarin ighhlights VASCEPA/VAZKEPA positioning amid advances in triglyceride management
Grafa
Health

MapLight Therapeutics accelerates Phase 2 enrollment, narrows topline data timing to Q3 2026

California-based MapLight Therapeutics (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, provided an update on the progress of its two ongoing Phase 2 studies.

Leia mais: MapLight Therapeutics accelerates Phase 2 enrollment, narrows topline data timing to Q3 2026
Grafa
Technology

Meta seals record 6.6 GW nuclear deal to fuel AI ambitions

Meta Platforms (NASDAQ:META) said Friday it has signed 20-year power purchase agreements to buy electricity from three Vistra Corp. nuclear plants in the U.S. Midwest and entered development partnerships with two companies pursuing small modular reactor technology, as Big Tech races to lock in reliable, long-term energy supplies for expanding artificial intelligence and data center operations.

Leia mais: Meta seals record 6.6 GW nuclear deal to fuel AI ambitions